Atlas Arteria Crecimiento futuro

Future controles de criterios 4/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Atlas Arteria de 21.8% y 15.9% por año respectivamente. Se prevé que el BPA crezca en un 22.9% al año. Se espera que la rentabilidad financiera sea de 8.2% en 3 años.

Información clave

21.8%

Tasa de crecimiento de los beneficios

22.9%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Infrastructure	19.0%
Tasa de crecimiento de los ingresos	15.9%
Rentabilidad financiera futura	8.2%
Cobertura de analistas	Good
Última actualización	19 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Is Now An Opportune Moment To Examine Atlas Arteria Limited (ASX:ALX)?

Apr 07

What Does Atlas Arteria Limited's (ASX:ALX) Share Price Indicate?

Dec 22

Is There An Opportunity With Atlas Arteria Limited's (ASX:ALX) 43% Undervaluation?

Aug 10

Is Atlas Arteria (ASX:ALX) Using Too Much Debt?

May 31

Is There An Opportunity With Atlas Arteria Limited's (ASX:ALX) 48% Undervaluation?

Apr 14

Debra Goodin Is The Independent Chairman of the Board of Atlas Arteria Limited (ASX:ALX) And They Just Picked Up 54% More Shares

Mar 03

Here's Why Atlas Arteria (ASX:ALX) Can Afford Some Debt

Feb 27

Atlas Arteria (ASX:ALX) Has Compensated Shareholders With A Respectable 78% Return On Their Investment

Jan 31

Atlas Arteria Limited (ASX:ALX) Shares Could Be 44% Below Their Intrinsic Value Estimate

Dec 27

How Many Atlas Arteria Limited (ASX:ALX) Shares Do Institutions Own?

Dec 06

Is There Now An Opportunity In Atlas Arteria Limited (ASX:ALX)?

Nov 19

Atlas Arteria (ASX:ALX) Has Gifted Shareholders With A Fantastic 142% Total Return On Their Investment

Jul 30

Previsiones de crecimiento de beneficios e ingresos

ASX:ALX - Estimaciones futuras de los analistas y datos financieros pasados (AUD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	229	542	770	771	4
12/31/2025	210	477	572	731	5
12/31/2024	199	393	548	695	5
6/30/2024	140	300	87	88	N/A
3/31/2024	137	312	86	86	N/A
12/31/2023	134	324	84	85	N/A
9/30/2023	131	315	86	87	N/A
6/30/2023	128	307	89	90	N/A
3/31/2023	123	287	81	82	N/A
12/31/2022	118	267	73	74	N/A
9/30/2022	115	264	65	66	N/A
6/30/2022	111	260	56	58	N/A
3/31/2022	106	222	51	53	N/A
12/31/2021	101	183	46	48	N/A
9/30/2021	96	134	37	41	N/A
6/30/2021	91	85	29	35	N/A
3/31/2021	99	13	29	37	N/A
12/31/2020	107	-60	29	39	N/A
9/30/2020	128	-37	40	52	N/A
6/30/2020	149	-14	52	64	N/A
3/31/2020	162	2	56	70	N/A
12/31/2019	175	17	61	76	N/A
9/30/2019	167	17	43	56	N/A
6/30/2019	159	18	25	35	N/A
3/31/2019	146	47	24	29	N/A
12/31/2018	132	77	22	23	N/A
9/30/2018	126	78	34	34	N/A
6/30/2018	120	78	45	46	N/A
3/31/2018	101	270	N/A	32	N/A
12/31/2017	83	462	N/A	18	N/A
9/30/2017	54	506	N/A	-4	N/A
6/30/2017	25	550	N/A	-25	N/A
3/31/2017	14	388	N/A	-20	N/A
12/31/2016	3	225	N/A	-16	N/A
9/30/2016	2	162	N/A	-14	N/A
6/30/2016	2	99	N/A	-13	N/A
3/31/2016	2	92	N/A	-27	N/A
12/31/2015	2	85	N/A	-42	N/A
9/30/2015	3	71	N/A	-41	N/A
6/30/2015	3	58	N/A	-40	N/A
3/31/2015	2	4	N/A	-32	N/A
12/31/2014	2	-51	N/A	-25	N/A
6/30/2014	2	-47	N/A	-25	N/A
3/31/2014	1	-3	N/A	-7	N/A
12/31/2013	1	42	N/A	11	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (21.8% al año) de ALX es superior a la tasa de ahorro (2.6%).

Beneficios vs. Mercado: Se prevé que los beneficios (21.8% al año) de ALX crezcan más rápidamente que el mercado Australian (12.4% al año).

Beneficios de alto crecimiento: Se espera que los beneficios de ALX crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (15.9% al año) de ALX crezcan más rápidamente que los del mercado Australian (5.7% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 15.9% al año) de ALX crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de ALX sea baja dentro de 3 años (8.2%).

Atlas Arteria Crecimiento futuro

Future controles de criterios 4/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus revenue estimates fall by 13%

Consensus EPS estimates fall by 11%

Consensus EPS estimates fall by 15%

Consensus revenue estimates increase by 10%

Price target decreased to AU$6.96

Consensus EPS estimates fall by 14%

Recent updates

First half dividend of AU$0.20 announced

Atlas Arteria Limited Announces Distribution for the Six Months Ended 30 June 2024, Payable on 7 October 2024

High number of new directors

Consensus revenue estimates fall by 13%

First half 2024 earnings: EPS and revenues miss analyst expectations

Now 20% undervalued after recent price drop

Atlas Arteria Limited Appoints Hugh Wehby as Managing Director

Atlas Arteria Limited to Report First Half, 2025 Results on Aug 28, 2025

Final dividend of AU$0.20 announced

Atlas Arteria Limited Announces the Retirement of Graeme Bevans as CEO and Managing Director

Atlas Arteria Limited Announces Distribution for the Six Months Ended 31 December 2023, Payable on 8 April 2024

Atlas Arteria Limited, Annual General Meeting, May 15, 2024

Atlas Arteria Limited, Annual General Meeting, May 16, 2024

Full year 2023 earnings released: EPS: AU$0.22 (vs AU$0.25 in FY 2022)

Atlas Arteria Appoints Laura Hendricks to the Board as an Independent Non-Executive Director

Atlas Arteria Limited Announces Distribution for the Six Months Ended 30 June 2023, Estimated Payment Date Is 5 October 2023

Atlas Arteria Limited Announces Distribution for the Six Months Ended 30 June 2023, Payable on 5 October 2023

Consensus EPS estimates fall by 11%

First half 2023 earnings released: EPS: AU$0.12 (vs AU$0.13 in 1H 2022)

Atlas Arteria Limited Reaffirms Distribution Guidance for the First Half and Second Half of 2023

Atlas Arteria Limited to Report First Half, 2024 Results on Aug 29, 2024

Atlas Arteria Limited Appoints Ken Daley as Director

Atlas Arteria Limited Announces Caroline Foulger Will Retire as A Director, with Effect from 1 July 2023

Consensus EPS estimates fall by 15%

Full year 2022 earnings released: EPS: AU$0.25 (vs AU$0.19 in FY 2021)

Insufficient new directors

Atlas Arteria Limited Announces Board Changes

Atlas Arteria Limited (ASX:ALX) completed the acquisition of 66.67% stake in Skyway Concession Company, LLC from CPP Investments and OMERS Infrastructure.

Now 20% undervalued after recent price drop

Atlas Arteria Limited, Annual General Meeting, Apr 27, 2023

Consensus revenue estimates increase by 10%

Atlas Arteria Limited to Report Q4, 2022 Results on Feb 23, 2023

Price target decreased to AU$6.96

Investor sentiment deteriorated over the past week

Atlas Arteria Limited Provides Distribution Guidance for the Year 2023

Atlas Arteria Limited (ASX:ALX) entered into an agreement to acquire a 66.67% stake in Skyway Concession Company, LLC for $2 billion.

Consensus EPS estimates fall by 14%

First half 2022 earnings released: EPS: AU$0 (vs AU$0.074 in 1H 2021)

Atlas Arteria Limited Provides Dividend Guidance for the First Half of 2022

Price target increased to AU$7.40

Investor sentiment improved over the past week

Atlas Arteria Limited Announces Executive Changes

Is Now An Opportune Moment To Examine Atlas Arteria Limited (ASX:ALX)?

Independent Non-Executive Director recently bought AU$76k worth of stock

Full year 2021 earnings: EPS and revenues miss analyst expectations

What Does Atlas Arteria Limited's (ASX:ALX) Share Price Indicate?

Insider recently bought AU$67k worth of stock

First half 2021 earnings released: EPS AU$0.074 (vs AU$0.14 loss in 1H 2020)

Is There An Opportunity With Atlas Arteria Limited's (ASX:ALX) 43% Undervaluation?

Is Atlas Arteria (ASX:ALX) Using Too Much Debt?

Price target decreased to AU$6.21

Is There An Opportunity With Atlas Arteria Limited's (ASX:ALX) 48% Undervaluation?

Debra Goodin Is The Independent Chairman of the Board of Atlas Arteria Limited (ASX:ALX) And They Just Picked Up 54% More Shares

Independent Chairman of the Board recently bought AU$100k worth of stock

Here's Why Atlas Arteria (ASX:ALX) Can Afford Some Debt

Full year 2020 earnings released: AU$0.061 loss per share (vs AU$0.024 profit in FY 2019)

Atlas Arteria Limited Announces Board Changes

New 90-day low: AU$5.97

Atlas Arteria Limited to Report Fiscal Year 2020 Results on Feb 25, 2021

Atlas Arteria (ASX:ALX) Has Compensated Shareholders With A Respectable 78% Return On Their Investment

Atlas Arteria Limited, Annual General Meeting, Apr 27, 2021

Atlas Arteria Limited (ASX:ALX) Shares Could Be 44% Below Their Intrinsic Value Estimate

How Many Atlas Arteria Limited (ASX:ALX) Shares Do Institutions Own?

Is There Now An Opportunity In Atlas Arteria Limited (ASX:ALX)?

Atlas Arteria Limited Announces Changes to its Board

New 90-day low: AU$5.95

New 90-day low: AU$6.07

New 90-day low - AU$6.10

Atlas Arteria Limited (ASX:ALX) acquired 6.14% stake in APRR and ADALEC from Macquarie European Infrastructure Fund II managed by Macquarie Infrastructure and Real Assets (Europe) Limited.